AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Posted: October 13, 2022 at 2:26 am

Company expects to commence patient enrollment and dosing in Q1 2023 Company expects to commence patient enrollment and dosing in Q1 2023

More here:
AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Related Posts